WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2017184626) COLD ADAPTED AND VIRULENCE FACTOR DELETED LIVE ATTENUATED VACCINE SUITABLE FOR MUCOSAL DELIVERY
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.:    WO/2017/184626    International Application No.:    PCT/US2017/028170
Publication Date: 26.10.2017 International Filing Date: 18.04.2017
IPC:
A61K 39/145 (2006.01), A61K 39/00 (2006.01)
Applicants: EMERGING VIRAL VACCINE LIMITED [CN/CN]; c/o Comprehensive Drug Enterprises Limited 608-613 IC Development Center 6 Science Park West Avenue Hong Kong Science Park Hong Kong (CN).
LAU, Johnson Yiu-Nam [US/US]; (US)
Inventors: LAU, Johnson Yiu-Nam; (US).
CHEN, Honglin; (CN).
ZHENG, Min; (CN).
WANG, Pui; (CN).
LAU, Johnson Yiu-Nam; (US).
YEUN, Kwok Yung; (CN)
Agent: BRILLHART, Kurt; (US).
ANDELIN, Joseph A.; (US).
CASTANEDA, Steven; (US).
DEAN, Ryan S.; (US).
FESSENMAIER, Martin; (US).
FISH, Robert D.; (US).
HALPENNY, Genevieve; (US).
KIM, Rosie; (US).
MAR, Andrew; (US).
PRIETO, Tomas; (US).
SHIN, Minyoung; (US).
TSANG, Mei; (US)
Priority Data:
62/324,134 18.04.2016 US
Title (EN) COLD ADAPTED AND VIRULENCE FACTOR DELETED LIVE ATTENUATED VACCINE SUITABLE FOR MUCOSAL DELIVERY
(FR) VACCIN VIVANT ATTÉNUÉ SANS FACTEUR DE VIRULENCE ET ADAPTÉ AU FROID APPROPRIÉ À UNE ADMINISTRATION MUCOSALE
Abstract: front page image
(EN)Compositions and methods are provided for a live, attenuated influenza vaccine suitable for nasal administration. The vaccine utilizes a cold adapted influenza virus that lacks virulence factor, and includes mutations that provide replicative ability sufficient for vaccine manufacture. Vaccines so produced provide significant cross protection for non-vaccinating strains. The vaccine is safe for children under the age of 2 and adults over 49 years of age. In addition, the cold adapted, virulence factor deleted influenza virus can be adapted to provide immunity to non-influenza pathogens.
(FR)L'invention concerne des compositions et des procédés pour un vaccin vivant atténué contre la grippe approprié pour une administration nasale. Le vaccin utilise un virus de la grippe adapté au froid qui est dépourvu de facteur de virulence, et comprend des mutations qui fournissent une capacité de reproduction suffisante pour la fabrication de vaccins. Les vaccins ainsi produits fournissent une protection croisée significative pour des souches non vaccinales. Le vaccin est sans danger pour les enfants de moins de 2 ans et les adultes de plus de 49 ans. De plus, le virus contre la grippe sans facteur de virulence, adapté au froid, peut être conçu pour conférer une immunité aux pathogènes non grippaux.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)